Denali Therapeutics Soars: New Director Sparks 1.18% Gain!

miércoles, 4 de junio de 2025, 12:38 pm ET1 min de lectura
DNLI--
Denali Therapeutics Inc. rose 1.18% in intraday trading, with the company electing Julian Baker as a Class II director at its annual general meeting held on June 03, 2025. Baker will serve until the 2028 annual meeting or until his successor is elected.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios